Platelet‐to‐Neutrophil Ratio: A Novel Prognostic Indicator for Anti‐PD‐1‐Based Therapy in Relapsed/Refractory Hodgkin Lymphoma and Solid Tumors
ABSTRACT Program cell death‐1 (PD‐1) blockade treatment has been shown effective in cases with relapsed/refractory classical Hodgkin Lymphoma (R/R cHL), while prognostic biomarkers remain unclear. Seventy‐seven cases with R/R cHL who received immunotherapy for the first time were included. Receiver...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70199 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ABSTRACT Program cell death‐1 (PD‐1) blockade treatment has been shown effective in cases with relapsed/refractory classical Hodgkin Lymphoma (R/R cHL), while prognostic biomarkers remain unclear. Seventy‐seven cases with R/R cHL who received immunotherapy for the first time were included. Receiver operator characteristic analysis displayed platelet‐to‐neutrophil ratio (PNR) as the most probable indicator among distinct inflammatory‐cell ratios. Patients with high pretreatment PNR (≥ 51.6) achieved significantly higher complete response (CR) rate as compared with patients with low PNR (< 51.6), and PNRhigh patients displayed significantly longer progression‐free survival (PFS) versus PNRlow patients (p = 0.001). Cox analysis indicated PNR as an independent factor for prognosis (hazard ratio, 0.34, 95% CI, 0.18–0.65, p = 0.001). Among patients acquiring CR, higher PNR was associated with improved PFS and relapse‐free survival. Moreover, PNR correlations with CR rate and PFS were validated in external cohort of cHL. Notably, PNR was also a strong prognostic biomarker for PFS and overall survival after anti‐PD‐1 combination therapy in patients with solid tumors, such as biliary tract carcinoma, gastric carcinoma, or colon cancer. In conclusion, this study for the first time reveals a correlation between pretreatment peripheral PNR and prognosis of anti‐PD‐1‐based therapy in patients with relapsed/refractory cHL and advanced solid tumor. |
|---|---|
| ISSN: | 2688-2663 |